BUSINESS

JCR, Teijin Launch Japan PI/PII of Regenerative Medicine Product for Cerebral Infarction

February 7, 2019
JCR Pharmaceuticals and Teijin said on February 6 that the first patient has received dosing in PI/II studies of JTR-161, an allogeneic regenerative medicine product made up of dental pulp-derived stem cells (DPCs), in Japan for the treatment of cerebral…

To read the full story

Related Article

BUSINESS

Nichi-Iko Pharmaceutical is off to a new start making the former Elmed Eisai its wholly owned subsidiary on April 1.…

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

By Yoshinori Sagehashi

Japan is to not use its new cost-effectiveness assessment (CEA) scheme for reimbursement decisions - at least for now -…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…